Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines

• Main Authors: Kulkarni Hemant (Author), Göring Harald H H (Author), Diego Vincent (Author), Cole Shelley (Author), Walder Ken R (Author), Collier Greg R (Author), Blangero John (Author), Carless Melanie A (Author)
• Format: Book
• Published: BMC, 2012-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<p>Abstract</p> <p>Background</p> <p>Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity. Given that drug cyto...